Development Expansion
Facility design and regulatory planning are complete, enabling the next phase of construction to commercial capacity.

Cannhill SAS integrates pharmaceutical cultivation, European governance, and distribution, designed to supply Europe's regulated pharmaceutical markets at commercial scale.
Facility design and regulatory planning are complete, enabling the next phase of construction to commercial capacity.
Cultivation, manufacturing, and export licenses secured for regulated international pharmaceutical markets.
Designed around European GMP compliance and direct international distribution.
Structured under a Dutch holding framework, providing predictable investor oversight, legal transparency, and institutional asset protection.
Indoor-grade flower quality at greenhouse operational costs, leveraging Colombia's equatorial sunlight and natural climate advantage.
End-to-end licensing aligned with international narcotic boards, supporting import and distribution permits across the EU.
Modular expansion capacity built to supply Europe's regulated pharmaceutical markets reliably, year-round.
Cannhill SAS, a subsidiary of Agritech Invest Holding BV in the Netherlands, operates under an international model that combines Dutch governance, Colombian production, and European distribution into a scalable pharmaceutical supply chain.
Dutch Governance
Netherlands
Investment is held through Agritech Invest Holding BV in the Netherlands, providing stable governance, capital oversight, and a familiar and favorable European investment structure.
Pharmaceutical Production / Contract Manufacturer
Colombia
Pharmaceutical-grade cultivation and processing are carried out by Cannhill SAS in Colombia, combining world-class growing conditions with GACP and GMP standards.
Regulated Distribution
Netherlands
Cannhill Global Distribution BV coordinates commercial operations, quality assurance, regulatory compliance, and European market access, enabling efficient distribution across regulated pharmaceutical markets through GDP and GMP partners.
Investor Alignment
Cannhill is positioned to scale into regulated pharmaceutical markets.
For investors interested in learning more about the opportunity, further information on our strategy, operations, and growth plans is available.